{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"LTE60","restrictiveAgreement":true},"limitationsAndCaveats":{"description":"Enrollment stopped early at the recommendation of the DSMB due to interim analysis positive results and because of slow study enrollment related to an evolving treatment landscape for MPM and the COVID-19 pandemic."},"pointOfContact":{"email":"mlanglois@polarispharma.com","organization":"Polaris Pharmaceuitcals Inc","phone":"858-452-6688","phoneExt":"161","title":"Dr. Mirla Langlois"}}